

Phase 1 trial: Fortrea CRU code: 8526072

Submission date 04/08/2025	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/08/2025	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 04/08/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Jim Bush

Contact details

Drapers Yard
Leeds
United Kingdom
LS11 9EH
+44 113 394 5200
jim.bush@fortrea.com

Type(s)

Public, Scientific

Contact name

Dr . Project Management Department

Contact details

Chesterford Research Park
Cambridge
United Kingdom
CB10 1XL
+44 1799 531130
clinical@cellcentric.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

1009878

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Phase 1 trial: Fortrea CRU code: 8526072

Acronym

Nil known

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 30/10/2024, North East REC – York (2 Redman Place, London, E20 1JQ, United Kingdom; +44 207 104 8052; york.rec@hra.nhs.uk), ref: 24/NE/0157

Study design

Interventional

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Other

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

02/03/2025

Eligibility

Key inclusion criteria

Healthy human volunteer

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

Does not meet inclusion criteria

Date of first enrolment

29/01/2025

Date of final enrolment

04/02/2025

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Fortrea Clinical Research Unit Limited

Draper's Yard Marshall Street

Holbeck

Leeds

United Kingdom

LS11 9EH

Sponsor information

Organisation

CellCentric Limited

Funder(s)

Funder type

Industry

Funder Name

CellCentric Limited

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the publication of results of non-therapeutic clinical trials.

IPD sharing plan summary

Not expected to be made available